Emitted dose estimates from Seretide® Diskus® and Symbicort® Turbuhaler® following inhalation by severe asthmatics

International Journal of Pharmaceutics

Volumn 316, Issue 1-2, 2006, Pages 131-137

  Tarsin, Walid Y ^a   Pearson, Stanley B ^b   Assi, Khaled H ^a   Chrystyn, Henry ^a  

^a UNIVERSITY OF BRADFORD   (United Kingdom)

^b LEEDS GENERAL INFIRMARY   (United Kingdom)

Author keywords

Asthma; Diskus ; Dose; Electronic Lung ; Turbuhaler

Indexed keywords

BUDESONIDE; BUDESONIDE PLUS FORMOTEROL; DISKUS; FLUTICASONE PROPIONATE; FLUTICASONE PROPIONATE PLUS SALMETEROL; FORMOTEROL; FORMOTEROL PLUS BUDENOSIDE; SALMETEROL XINAFOATE; SALMETEROL XINAFOATE PLUS FLUTICASONE PROPIONATE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; ASTHMA; CLINICAL ARTICLE; CONTROLLED STUDY; EX VIVO STUDY; FEMALE; FLOW RATE; HUMAN; INFORMATION PROCESSING; INHALATION; MALE; PRIORITY JOURNAL;

ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; ADULT; AGED; ALBUTEROL; ANDROSTADIENES; ANTI-ASTHMATIC AGENTS; ASTHMA; BUDESONIDE; CROSS-OVER STUDIES; DRUG COMBINATIONS; ETHANOLAMINES; FEMALE; HUMANS; MALE; MIDDLE AGED; NEBULIZERS AND VAPORIZERS; PARTICLE SIZE; SEVERITY OF ILLNESS INDEX;

EID: 33646776034     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2006.02.040     Document Type: Article

References (24)

1. Ashurst I.C., Prime D., and Haywood P.A. Development of a dry powder inhaler device containing a combination of salmeterol and fluticasone propionate. Eur. Respir. J. 12 (1998) 93s
2. Assi K.H., and Chrystyn H. The different resistance of dry powder inhalers (DPIs). Am. J. Respir. Crit. Care Med. 163 (2001) A443
3. Bisgaard H., Klug B., Sumby B.S., and Burnell P.K.P. Fine particle mass from the Diskus inhaler and Turbuhaler inhaler in children with asthma. Eur. Respir. J. 11 (1998) 1111-1115
4. Bland J.M., and Altman D.G. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 8 (1986) 307-310
5. Brindley A., Sumby B.S., and Smith I.J. The characterisation of inhalation devices by an inhalation simulator; the Electronic Lung. J. Aerosol Med. 7 (1994) 197-200
6. Broeders M.E.A.C., Molema J., Vermue N.A., and Folgering H.T.M. Peak inspiratory flow rate and slope of inhalation profiles in dry powder inhalers. Eur. Respir. J. 18 (2001) 780-783
7. Broeders M.E.A.C., Molema J., Vermue N.A., and Folgering H.T.M. In Check Dial: accuracy for Diskus and Turbuhaler. Int. J. Pharm. 252 (2003) 275-280
8. Burnell P.K.P., Malton A., Reavill K., and Ball M. Design, validation and initial testing of the Electronic Lung. J. Aerosol Sci. 29 (1998) 1011-1025
9. Burnell P.K.P., Grant A.C., Haywood P.A., Prime D., and Sumby B. Powder inhalers-exploring the limits of performance. Respir. Drug Deliv. VI (1998) 259-266
10. Burnell P.K.P., Small T., Doig S., Johal B., Jenkins R., and Gibson G.J. Ex vivo product performance of Diskus and Turbuhaler inhalers using inhalation profiles from patients with severe chronic obstructive pulmonary disease. Respir. Med. 95 (2001) 324-330
11. Chrystyn H. Is inhalation rate important for a dry powder inhaler? Using the In-Check Dial to identify these rates. Respir. Med. 97 (2003) 181-187
12. Clark A.R., and Hollingworth A.M. The relationship between powder inhaler resistance and peak inspiratory conditions in healthy volunteers-implications for in vitro testing. J. Aerosol Med. 6 (1993) 99-110
13. ®. Allergy 104 (1989) 220-225
14. Everard M.L., Devadason S.G., and Le Soeuf P.N. Flow early in the inspiratory manoeuvre affects the aerosol particle size distribution from a Turbuhaler. Respir. Med. 91 (1997) 624-628
15. Ganderton D. General factors influencing drug delivery to the lung. Respir. Med. 91 (1997) 13-16
16. Ganderton D., and Kassem N.M. Dry powder inhalers. Adv. Pharm. Sci. (1992) 165-191
17. Martonen B., and Katz I.M. Deposition patterns of aerosolised drugs within human lungs. Effects of ventilatory parameters. Pharm. Res. 10 (1993) 871-878
18. Newman S.P., Moren F., Trofast E., Talaee N., and Clarke S.W. Terbutaline sulphate Turbuhaler: effect of inhaled flow rate on drug deposition and efficacy. Int. J. Pharm. 74 (1991) 209-213
19. Nielsen K.G., Skov M., Klug B., Ifversen M., and Bisgaard H. Flow-dependent effect of formoterol dry-powder inhaled from an Aerolizer. Eur. Respir. J. 10 (1997) 210-2109
20. Nunn A.J., and Gregg I. New regression equation for predicting peak expiratory flow in adults. BMJ 298 (1989) 1068-1070
21. Pauwels R.A. Inhalation device, pulmonary deposition and clinical effects of inhaled therapy. J. Aerosol Med. 10 (1997) S17-S21
22. Selroos O., Pietinhalho A., and Riska H. Delivery devices for inhaled asthma medications; clinical implications of differences in effectiveness. Clin. Immunother. 6 (1996) 273-279
23. Tarsin W., Assi K.H., and Chrystyn H. In vitro intra- and inter-inhaler flow rate-dependent dosage emission from a combination of budesonide and eformoterol in a dry powder inhaler. J. Aerosol Med. 17 (2004) 25-32
24. United States Pharmacopoeia, USP 24, NF 19, 2000. <601> Aerosols, Metered Dose Inhalers, and Dry Powder Inhalers, pp. 1895-1912.